Introduction to NDC 51407-0052
NDC 51407-0052 corresponds to Carvedilol Phosphate, a medication manufactured by Golden State Medical Supply, Inc. Carvedilol is primarily used in the treatment of high blood pressure and heart failure.
Market Context
Biopharma and Biotech Industry Growth
The biopharma and biotech industries are experiencing significant growth, driven by technological advancements, evolving regulatory frameworks, and a shift towards patient-centered care. The biopharma market is projected to grow at a CAGR of 7.56% between 2024 and 2029, reaching over $400 billion by 2029[1].
Therapeutic Area and Market Trends
Hypertension and Heart Failure Market
Carvedilol Phosphate falls under the therapeutic area of cardiovascular diseases, specifically hypertension and heart failure. This market is characterized by a high demand for effective treatments due to the prevalence of these conditions.
- Prevalence: Hypertension and heart failure are among the leading causes of morbidity and mortality globally, ensuring a consistent demand for medications like Carvedilol Phosphate.
- Competitive Landscape: The market for hypertension and heart failure treatments is highly competitive, with both branded and generic options available. Carvedilol Phosphate, being a generic medication, competes with other generic and branded beta-blockers[4].
Drug Identification and Specific Market Analysis
Carvedilol Phosphate
- Manufacturer: Golden State Medical Supply, Inc.
- Indications: Carvedilol Phosphate is used to treat high blood pressure and heart failure.
- Formulation: Available in various strengths, typically in tablet form.
Factors Influencing Pricing
Regulatory Changes
Regulatory changes can impact pricing by altering how drugs are tracked, listed, and reimbursed. For instance, changes in establishment registration and drug listing requirements can affect the overall cost structure of the medication[1].
Market Competition
The presence of both generic and branded competitors in the hypertension and heart failure market influences the pricing of Carvedilol Phosphate. Generic versions of similar medications can drive prices down, while branded medications may maintain higher prices due to their brand loyalty and perceived efficacy.
Technological Advancements
Technological innovations in drug development and manufacturing can lead to more efficient production processes, potentially reducing costs. However, for established generic medications like Carvedilol Phosphate, these advancements may have a minimal direct impact on pricing[1].
Patent Status
Carvedilol Phosphate is a generic medication, meaning its patent has expired. This allows multiple manufacturers to produce the drug, increasing competition and generally leading to lower prices.
Price Projections for NDC 51407-0052
Current Pricing
As of recent data, the pricing for Carvedilol Phosphate can vary based on the strength and quantity of the medication. Here is an example of current pricing for similar strengths:
- Carvedilol 6.25 mg tablets: Prices can range from $0.20 to $0.50 per tablet, depending on the pharmacy and location[2].
Future Projections
Given the competitive nature of the generic drug market, prices for Carvedilol Phosphate are likely to remain stable or decrease slightly over time.
- Generic Competition: The entry of new generic manufacturers can further reduce prices.
- Regulatory Stability: Assuming no significant regulatory changes, the pricing environment is expected to remain relatively stable.
- Market Demand: Consistent demand for hypertension and heart failure treatments will maintain a stable market for Carvedilol Phosphate, but prices are unlikely to increase significantly due to competition[1].
Example Pricing Trends
For illustrative purposes, here is a hypothetical scenario:
- Current Pricing: $0.30 per tablet for a 6.25 mg strength.
- Future Projections: With increased generic competition, prices might drop to $0.20 to $0.25 per tablet over the next few years.
Key Takeaways
- NDC Importance: The National Drug Code (NDC) is crucial for identifying and tracking medications, ensuring accurate inventory management and reimbursement.
- Market Trends: The biopharma and biotech industries are growing, but the generic drug market, where Carvedilol Phosphate resides, is highly competitive.
- Pricing Factors: Pricing is influenced by competition, regulatory changes, and technological advancements, though these factors have a minimal impact on established generic medications.
- Specific Analysis: To provide precise price projections, it is essential to identify the drug and analyze its specific market context, including competition and regulatory environment.
FAQs
1. What is the primary use of Carvedilol Phosphate?
Carvedilol Phosphate is primarily used to treat high blood pressure and heart failure.
2. How does the generic status of Carvedilol Phosphate affect its pricing?
The generic status of Carvedilol Phosphate leads to increased competition, which generally results in lower prices compared to branded medications.
3. What are the key drivers of growth in the biopharma and biotech industries?
Key drivers include technological advancements, evolving regulatory frameworks, and a shift towards patient-centered care and precision medicine[1].
4. How do regulatory changes impact pharmaceutical pricing?
Regulatory changes can affect pricing by altering how drugs are tracked, listed, and reimbursed. For example, changes in establishment registration and drug listing requirements can impact the cost structure of medications[1].
5. What role does competition play in the pricing of generic medications like Carvedilol Phosphate?
Competition from other generic manufacturers drives prices down, ensuring that medications like Carvedilol Phosphate remain affordable for patients.
Sources
- DrugPatentWatch: Latest drug prices and trends for NDC 51407-0013[1].
- Missouri Specialty MAC: List of drugs with their NDC and prices effective January 1, 2023[2].
- Komodo Health: Drug projections using real-time data and advanced models[3].
- FindACode: List of drugs by Golden State Medical Supply, Inc., including Carvedilol Phosphate[4].
